The San Antonio Breast Cancer Symposium (SABCS) and its co-sponsor the American Association of Cancer Research (AACR), award scholarships every year to researchers to help their work be seen. The researchers are typically early in their career.

Below are the winners of the scholarships for #SABCS21. To see their work, register for the symposium online by Nov. 17 at www.sabcs.org.

Tahaney

Rana

Bhardwaj

Cervia

Semina

SABCS Basic Science Scholar Award Recipients — For laboratory-based investigators-in-training whose work focuses on the biology of breast cancer and preclinical models of its development and progression.

• William M. Tahaney, PhD, The University of Texas MD Anderson Cancer Center, Houston: Inhibition of GPX4 induces preferential death of p53-mutant triple-negative breast cancer cells, GS1-09 Tuesday, Dec. 7, 10:15 a.m.
• Priyanka S. Rana, PhD, The MetroHealth System, Case Western Reserve University, Cleveland: Targeted deletion of Kindlin-2 in mouse mammary glands inhibits tumor growth, invasion and metastasis downstream of TGF-β/EGF oncogenic signaling pathway, P1-06-02 Wednesday, Dec. 8, 7 a.m.
• Priya Bhardwaj, BA, Weill Cornell Medicine, New York: Obesity is associated with DNA damage in the breast epithelium of BRCA1 and BRCA2 mutation carriers: A role for estrogens & strategies for prevention, P2-06-03 Wednesday, Dec. 8, 5 p.m.
• Lisa D. Cervia, PhD, Dana-Farber Cancer Institute and Broad Institute of MIT and Harvard, Boston: A ubiquitination cascade regulating the integrated stress response and survival in carcinomas, P3-09-01 Thursday, Dec. 9, 7 a.m.
• Svetlana E. Semina, PhD, University of Illinois at Chicago (UIC), Dept. of Physiology and Biophysics, College of Medicine, Chicago: Identification of novel ER and ER-NFκB driven stem-like cell populations in ER+ breast cancer, P5-11-01 Friday, Dec. 10, 7 a.m.

Kyalwazi

Safonov

Abravanel

Douglas

Iqbal

SABCS Clinical Scholar Award Recipients — For clinical scientists-in-training who are actively pursuing clinical or clinical/translational research in breast cancer.

• Beverly Kyalwazi, BS, University of Chicago Pritzker School of Medicine, Chicago: Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial, GS4-02 Friday, Dec. 10, 9 a.m.
• Anton Safonov, MD, Memorial Sloan Kettering Cancer Center, New York: Comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistance, GS4-08 Friday, Dec. 10, 10:30 a.m.
• Daniel L. Abravanel, MD, PhD, Dana-Farber Cancer Institute, Boston: Spatio-molecular dissection of the breast cancer metastatic microenvironment, PD6-03 Wednesday, Dec. 8, 5 p.m.
• Sasha R. Douglas, MD, UC San Diego, La Jolla, Calif.: Trends in surgical resection for stage IV breast cancer: Less surgery more systemic treatment, PD7-06 Thursday, Dec. 9, 7 a.m.
• Ramsha Iqbal, MD, Amsterdam UMC, Noord-Holland, Netherlands: Towards a new standard for staging: A comparative study of [18F]FES PET/CT vs [18F] FDG PET/CT in patients with clinical stage II/III and locoregional recurrent estrogen receptor positive breast cancer, P3-02-11 Thursday, Dec. 9, 7 a.m.

Pfob

Sirvén

Hensing

Nguyen

Peng

Coltman Scholar Award Recipients — In memory of Dr. Charles A. Coltman, co-founder of SABCS, to commemorate the significant contributions he made to oncology medicine. For clinical scientists-in-training.

• André Pfob, MD, Heidelberg University Hospital, Heidelberg, Germany: Intelligent vacuum-assisted breast biopsy to identify breast cancer patients with pathologic complete response after neoadjuvant systemic treatment for omission of breast and axillary surgery, PD7-02 Thursday, Dec. 9, 7 a.m.
• Milana Arantza Bergamino Sirvén, MD, The Institute of Cancer Research, London: HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer, PD15-02 Friday, Dec. 10, 7 a.m.
• Whitney L. Hensing, MD, MSCR, Washington University in St. Louis, St. Louis, Mo.: Genetic alterations detected by circulating tumor DNA (ctDNA) in HER2-low metastatic breast cancer (MBC), P2-01-01 Wednesday, Dec. 8, 5 p.m.
• Ha-Linh Nguyen, MS, KU Leuven, Leuven, Belgium: The association between genomic alterations and body mass index in patients with early breast cancer, P3-09-18 Thursday, Dec. 9, 7 a.m.
• Cheng Peng, ScD, Brigham and Women’s Hospital, Harvard Medical School, Boston: Regular aspirin use, breast tumor characteristics, and long-term breast cancer survival, P3-12-01 Thursday, Dec. 9, 7 a.m.

Wei

Kim

Glencer

Liu

Huang

AACR Associate Member Award Recipients — For presenters of meritorious abstracts who are Associate Members of the American Association for Cancer Research (AACR).

• Lixuan Wei, PhD, Mayo Clinic, Rochester, MN.: Estrogen receptor is a target of enzalutamide in ER+ breast cancer, PD1-03 Wednesday, Dec. 8, 7 a.m.
• Gun Min Kim, MD, UT Southwestern Simmons Cancer Center, Dallas: Combined inhibition of CDK4/6 and AKT is effective in Rb-intact triple-negative breast cancer of the luminal androgen receptor (LAR) subtype, PD3-07 Wednesday, Dec. 8, 7 a.m.
• Alexa Glencer, MD, University of California San Francisco, San Francisco: The tumor immune microenvironment and HER2 landscape of high-risk ductal carcinoma in situ: The DEFENSE study, P1-05-01 Wednesday, Dec. 8, 7 a.m.
• Yuxi Liu, MS, Harvard T.H. Chan School of Public Health, Boston: A genome-wide association study of mammographic texture variation, P3-13-02 Thursday, Dec. 9, 7 a.m.
• Hsiao-Ching Huang, MPH, University of Illinois at Chicago, College of Pharmacy, Department of Pharmacy, Systems, Outcomes and Policy (PSOP), Chicago: Racial/ethnic differences in the benefit of adjuvant chemotherapy for breast cancer patients with an intermediate risk 21-gene recurrence score, P3-14-02 Thursday, Dec. 8, 7 a.m.

Deng

Valdes

Li

Officer

Phi

• Zhengyi Deng, MS, Johns Hopkins Bloomberg School of Public Health, Baltimore: Racial/ethnic disparities in cancer mortality after a second breast cancer, P3-14-05 Thursday, Dec. 9, 7 a.m.
• Arnaldo Andres Marin Valdes, MD, UT Southwestern Simmons Comprehensive Cancer Center, Dallas: A spectrum of secondary mutations in HER2 augment breast cancer cell growth and reduce neratinib sensitivity in HER2-mutant breast cancer, P4-01-02 Thursday, Dec. 9, 5 p.m
• Yihao Li, PhD, Dana-Farber Cancer Institute, Boston: FGFR inhibitor mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces therapeutic resistance in triple negative breast cancer, P4-01-04 Thursday, Dec. 9, 5 p.m.
• Adam Dunn Officer, BS, University of California San Diego, San Diego: A gene expression meta-analysis identifies microenvironment differences in cellular composition and cell-cell interactions associated with breast cancer invasion, P5-06-02 Friday, Dec. 10, 7 a.m.
• Lan Thi Hanh Phi, MS, MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston: TBK1 inhibition potentiates the efficacy of AXL-targeted therapy in aggressive breast cancer preclinical models, P5-08-10 Friday, Dec. 10, 7 a.m.